On September 28, the US House of Representatives voted 218-210 to pass H.R. 4365, the Department of Defense Appropriations Act, 2024, which includes $25 million for the Congressionally Directed Medical Research Program – Neurofibromatosis Research Program (CDMRP-NFRP)! This development brings us one step closer to securing critical funding for the CDMRP-NFRP, which has been a driver in NF research and supports the groundbreaking NF Clinical Trials Consortium.
The Senate has yet to pass its Fiscal Year (FY) 2024 defense spending bill. Once it does, the two chambers will need to resolve their differences for a compromise bill. The Children’s Tumor Foundation will continue to advocate for NF during this time and provide updates throughout the process.
